Hybridoma Loss Insurance.
Hybridoma Instability is Common and Costly.
Many factors, including long-term storage, repeated freeze-thaw cycles, improper handling, and contamination can all lead to failure of hybridoma survival causing permanent loss of important mAbs. Hybridoma cell lines are also known to undergo gene mutations and rearrangements over time, leading to antibody heterogeneity and batch-to-batch variability – ie. hybridomas can contain additional heavy or light chain genes resulting in impaired affinity and specificity to the target antigen; hybridomas also may lose the chromosome containing the antibody genes required for antibody generation.
Next generation protein sequencing (NGPS) can provide the amino acid sequence of any antibody to help recover from the loss, death or mutation of hybridoma cell lines. Indefinite access to the amino acid sequence can mean a limitless supply of commonly used antibodies through recombinant expression, providing an insurance policy in case they are discontinued. NGPS can also validate every batch of antibodies produced by hybridomas, confirming batch-to-batch consistency.
Services for Hybridoma Users.
We support all hybridoma users, reagent and kit manufacturers, and the drug development pipeline by securing and validating the protein sequence. Contact us to discover how we can help provide insurance for your valuable immunoreagents.
Antibody Sequencing & Discovery Services.
De Novo mAb Sequencing
Starting with only a small protein sample, resurrect or secure the mAb by obtaining the amino acid sequence even after the death or mutation of a hybridoma cell line.
Explore Monoclonal Antibody Sequencing Services
Quality Control and Troubleshooting
Save time troubleshooting cell line stability issues throughout your pipeline, and routinely confirm that the sequences of manufactured immunoreagents match the expected sequences.
Explore Peptide Mapping Service
Recombinant Expression
Secure the protein sequence and safeguard a limitless mAb supply through recombinant expression, and for IP applications, in a streamlined workflow.
Explore Antibody Expression Services
Application Publications.
Tackling Reproducibility in Life Sciences with Protein Sequencing
Written by: Genya Gorshtein, MSc Published: May 9, 2023 Contents Introduction Hybridoma Instability [...]
De Novo Protein Sequencing vs DNA Sequencing
DNA sequencing is the process of determining the precise order of four nucleotides bases—adenine (A), guanine (G), cytosine (C), and thymine (T)—that make up the DNA molecule. From Sanger sequencing to next-generation sequencing (NGS), DNA sequencing’s accessibility and ease of use make it one of the most widely used technologies in life sciences.
Antibody Inaccuracy, Non-specificity and Irreproducibility at The Root of Research Extinction
Antibodies are integral to life sciences research and therapeutic and diagnostics discovery and development. However, they are inherently prone to variability.
Research Insurance with De Novo Protein Sequencing
If you could have guaranteed stability, certainty, and reproducibility for your research, would you be interested? Imagine this, if you’re 2 years into your project and your freezer died along with all of your important cell lines, what would you do? This is just one of the situations covered in this webinar, along with many other solutions researchers have begun to implement to safeguard their efforts. Whether you’re looking to proceed with stability and certainty or you’re looking for an immediate solution for your current reproducibility challenges, protein sequencing may be the answer.
“The sequences have allowed us to have an “insurance policy” of sorts for critical proteins used in our various products.”
David Ankrapp, Senior Research Scientist, NEOGEN
Talk to Our Scientists.
We Have Sequenced 10,000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.
Talk to Our Scientists.
We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics